Plus Therapeutics (PSTV) Registration Filing summary

Company overview and business model

• Develops targeted radiotherapeutics for central nervous system (CNS) cancers using advanced platform technologies, including nanoliposomes and microspheres encapsulating rhenium isotopes.

• Lead candidate, rhenium (186Re) obisbemeda, targets CNS cancers such as recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers via localized delivery.

• Acquired CNSide® diagnostic portfolio for cerebrospinal fluid cancer, currently in clinical trials, and is seeking partnership opportunities for this intellectual property.

• Operates a cGMP-validated R&D and manufacturing facility in San Antonio, Texas, with a robust supply chain for clinical and future commercial production.

Financial performance and metrics

• As of October 3, 2024, public float was approximately $10.6 million, with 5,896,333 shares outstanding and 5,750,160 held by non-affiliates.

• Last reported sale price of common stock on Nasdaq was $1.30 per share on October 3, 2024.

• No securities sold under General Instruction I.B.6 of Form S-3 in the prior 12-month period.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including R&D, clinical and preclinical expenditures, manufacturing, commercialization, working capital, capital expenditures, acquisitions, and investments.